Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo™ at the 39th European College of Neuropsychopharmacology (ECNP) Congress
Business Wire•09/10/2026•07:00 ET
0
Key Highlights
- ➤GlyphAgo increased agomelatine bioavailability 6.8-fold versus unmodified agomelatine
- ➤GlyphAgo showed 10-fold lower pharmacokinetic variability than unmodified agomelatine
- ➤Phase 1 data showed dose-dependent exposure increases without accumulation over seven days
- ➤Phase 2a generalized anxiety disorder trial underway; topline results expected early 2028
- ➤Seaport plans Phase 2/3 generalized anxiety disorder trial in first half of 2027
Expert Statements
Daniel Bonner, Ph.D., Co-Founder and Senior Vice President, Platform, Seaport Therapeutics
“The data presented at ECNP provide important clinical validation that our Glyph™ platform can meaningfully improve the pharmacokinetic profile of medicines historically limited by high first-pass liver metabolism.”
Daniel Bonner, Ph.D., Co-Founder and Senior Vice President, Platform, Seaport Therapeutics
“The increased exposure and markedly reduced inter-individual variability observed in the Phase 1 program are particularly compelling.”
Daniel Bonner, Ph.D., Co-Founder and Senior Vice President, Platform, Seaport Therapeutics
“More predictable drug exposure may translate into more consistent clinical outcomes for patients, further supporting the development of GlyphAgo as a potential treatment for generalized anxiety disorder.”
Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo™ at the 39(th) European College of Neuropsychopharmacology (ECNP) Congress
First scientific presentation of detailed PK data demonstrates dose-dependent increases in agomelatine exposure, no food effect, and no accumulation of exposure over seven days of dosing
Get started
Create a free account to read the full story.